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The identification of the calcium-sensing receptor (CaSR) and
the clarification of its role as the major regulator of
parathyroid gland function have important implications for
understanding the pathogenesis and evolution of secondary
hyperthyroidism in chronic kidney disease (CKD). Signaling
through the CaSR has direct effects on three discrete
components of parathyroid gland function, which include
parathyroid hormone (PTH) secretion, PTH synthesis, and
parathyroid gland hyperplasia. Disturbances in calcium and
vitamin D metabolism that arise owing to CKD diminish the
level of activation of the CaSR, leading to increases in PTH
secretion, PTH synthesis, and parathyroid gland hyperplasia.
Each represents a physiological adaptive response by the
parathyroid glands to maintain plasma calcium homeostasis.
Studies of genetically modified mice indicate that signal
transduction via the CaSR is a key determinant of parathyroid
cell proliferation and parathyroid gland hyperplasia. Because
enlargement of the parathyroid glands has important
implications for disease progression and disease severity, it is
possible that clinical management strategies that maintain
adequate calcium-dependent signaling through the CaSR will
ultimately prove useful in diminishing parathyroid gland
hyperplasia and in modifying disease progression.
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Secondary hyperparathyroidism (SHPT) is a common
consequence of chronic kidney disease (CKD).1,2 Major
traditional concerns about the disorder include metabolic
bone disease that occurs as a consequence of excess
parathyroid hormone (PTH) synthesis and secretion and
disturbances in calcium and phosphorus metabolism that
may contribute to the development of soft tissue and vascular
calcification. Recent observational studies have linked certain
biochemical abnormalities such as elevated levels of calcium
and phosphorus in serum to adverse clinical outcomes
among patients with stage 5 CKD who require treatment with
dialysis.3–5 These disturbances may arise either from the
disease itself or from the therapeutic interventions used to
manage it.2 The current review focuses more narrowly,
however, on the key determinants of parathyroid gland
function in CKD and the factors that influence the
development and progression of SHPT. Recent scientific
advances provide a much better understanding of the
molecular mechanisms and signal transduction pathways
involved in the pathogenesis of SHPT due to CKD and in the
regulation of PTH synthesis and secretion in this important
clinical disorder.
OVERVIEW
The natural history of SHPT is characterized by indolent
progression as the duration and severity of CKD increase.6,7
SHPT develops early during the course of progressive renal
insufficiency as an adaptive mechanism to maintain calcium
and possibly phosphorus homeostasis. Biochemical evidence
of abnormal parathyroid gland function is present in some
patients with stage 2, in many patients with stage 3, and in
most patients with stages 4 and 5 CKD, as judged by
elevations in plasma PTH levels.8,9 SHPT generally worsens
as a function of the number of years of treatment with
dialysis.10–12 It may progress ultimately to an advanced stage
that is refractory to medical treatment requiring surgical
management by parathyroidectomy.
Several abnormalities in parathyroid gland function
contribute to the persistent elevations in serum or plasma
PTH levels that characterize patients with SHPT. These
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include increases in PTH secretion by individual parathyroid
cells, increases in PTH production per cell owing to enhanced
gene expression and cellular enlargement or hypertrophy, and
increases in the total number of parathyroid cells because of
tissue hyperplasia.6,13–19 Abnormally high plasma PTH levels
have important adverse consequences on bone metabolism.
Reductions in bone mass, which affect cortical bone
primarily, are a characteristic feature of SHPT.20–23 Such
changes are common not only in persons with moderate
renal insufficiency but also in those with more advanced
CKD at the time regular dialysis began, and they are likely to
contribute substantially to the very high incidence of skeletal
fracture in the dialysis population.20,24 SHPT can also
aggravate hyperphosphatemia, a frequent and serious bio-
chemical abnormality among patients managed with con-
ventional dialysis regimens.25,26
The clinical management of SHPT is problematic because
current therapies do not fully correct the abnormalities
leading to its development and progression. Several reports
have documented that the need for surgical intervention to
definitively control SHPT increases as a function of the
number of years of treatment with dialysis.10 Indeed, despite
a modest decline during the mid-1990s, the annual rate of
parathyroidectomy in 2002 among patients undergoing
dialysis in the United States was no different than that
observed in 1992.27 Such findings suggest that conventional
approaches to the medical management of SHPT in patients
with CKD, which often include the use of large intravenous
doses of vitamin D sterols, do not effectively target one or
more key factors that account for disease progression. In this
regard, factors that regulate the cell cycle in general and the
growth and proliferation of parathyroid cells in particular
may prove ultimately to be extremely important determi-
nants of parathyroid gland hyperplasia, an integral compo-
nent of SHPT among patients with CKD that contributes
substantially to disease severity.28
Information about the physiology of the parathyroid
glands and the pathophysiology of parathyroid gland
function in various clinical disorders has increased markedly
in recent years. The calcium-sensing receptor (CaSR) and the
vitamin D receptor (VDR) together with recently identified
phosphate-regulating hormones represent the major deter-
minants of parathyroid gland function in CKD. The CaSR,
which was discovered by Brown, Hebert, and co-workers in
1993, plays a dominant role through G-protein-coupled
signal transduction pathways that modulate PTH secretion
directly.29,30 Signaling via the CaSR also affects other
components of parathyroid gland function that are relevant
to understanding the pathogenesis and progression of SHPT
among those with CKD. These include effects on pre-pro-
PTH gene transcription, PTH mRNA expression, and
parathyroid gland hyperplasia (Figure 1).19,30 Vitamin D
analogues, acting through vitamin D nuclear receptors,
regulate PTH mRNA expression, but they do not influence
PTH secretion directly.31,32 Hyperphosphatemia contributes
to the development and severity of hyperparathyroidism in
CKD, but the factors that mediate these effects, either directly
or indirectly in parathyroid tissue, remain to be deter-
mined.33 The respective roles of calcium and vitamin D as
discrete modifiers of parathyroid gland function have been
clarified further by studies of genetically modified mice.
PARATHYROID GLAND PHYSIOLOGY AND THE REGULATION
OF BLOOD-IONIZED CALCIUM LEVELS
Apart from being a major component of bone, calcium ions
serve crucial and diverse physiological functions. They act
both as first and second messengers in signal transduction in
a variety of cells, mediate synaptic function in neural tissue
and contractility in myocardial cells, and traverse cell
membranes through ion-specific channels.30 Because altera-
tions in the concentration of ionized calcium in extracellular
fluid can adversely affect many physiological processes, the
level of ionized calcium in blood is maintained normally
within a very narrow range.
PTH is the principal calcium-regulating hormone in man.
Parathyroid tissue evolved originally to allow animals to
adapt to life in the relatively calcium-deficient surroundings
of terrestrial compared with marine aquatic environments.
The parathyroid glands secrete PTH in a pulsatile manner
that is regulated by a calcium-sensing G-protein-coupled
receptor, or the CaSR, located on the surface of parathyroid
cells.34–36
The actions of PTH to regulate serum calcium concentra-
tions are mediated both directly and indirectly. Minute-to-
minute changes in PTH release into the circulation affect
serum calcium levels directly by modifying calcium transport
in the distal nephron and by affecting the exchange of
calcium between plasma and a rapidly exchangeable pool in
bone (Figure 2).34,35,37,38 The actions of PTH on calcium
transport in the distal nephron and on the miscible calcium
pool in bone occur within minutes to hours.39,40 Moreover,
the very steep slope of the inverse sigmoidal curve that
describes the relationship between blood-ionized calcium
and plasma PTH levels assures that small variations in
ionized calcium concentration elicit large reciprocal changes
in PTH secretion to modulate these fluxes appropriately.41
CaSR VDR
PTH secretion
Pre-pro-PTH gene  
transcription/PTH
synthesis
Parathyroid cell  
proliferation
Figure 1 | The respective roles of calcium ions, acting through the
CaSR, and vitamin D sterols, acting through the VDR, as direct
modifiers of parathyroid gland function.
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Ongoing short-term variations in PTH secretion that are
mediated by the CaSR thus provide a robust mechanism for
maintaining a constant level of ionized calcium in blood by
regulating continuously the amounts of calcium that enter or
leave the plasma compartment via the kidney and bone
(Figure 3).37–40
When short-term variations in calcium-regulated PTH
secretion are insufficient to fully maintain blood-ionized
calcium concentrations, additional compensatory responses
are invoked to restore baseline values. The case of
hypocalcemia will be discussed in some detail because it is
most relevant to understanding the pathogenesis of SHPT
due to CKD.
As mentioned previously, only minor changes in blood-
ionized calcium concentration increase PTH secretion
promptly and markedly.41–44 Plasma PTH levels rise within
minutes in normal volunteers when the blood-ionized
calcium level is lowered purposefully during intravenous
infusions of sodium citrate or other agents that chelate
calcium ions (Figure 4).43 Indeed, PTH levels increase
substantially before a measurable reduction in blood-ionized
calcium can be detected, results that demonstrate the
exquisite sensitivity of the CaSR in modulating PTH
secretion. As blood-ionized calcium levels decline progres-
sively, plasma PTH levels reach maximum values that are
approximately four- to fivefold higher than baseline after
20–30 min (Figure 4).43 They do not rise further, however,
when sustained reductions in blood-ionized calcium are
induced experimentally by continued infusions of sodium
citrate that are sufficient to overcome the immediate
corrective responses mediated by the kidney and bone as
summarized previously. A four- to fivefold increase in the
concentration of PTH in plasma thus represents the maximal
secretory response of the parathyroids to acute hypocalcemia
in human volunteers with normal renal and parathyroid
gland function.43,45,46 If very short-term increases in PTH
secretion are insufficient to prevent a decline in blood-
ionized calcium concentration and restore basal levels of the
CaSR activation, additional PTH is made available for
secretion by upregulating pre-pro-PTH gene transcription
and PTH synthesis.
The factors responsible for enhancing PTH gene expres-
sion during hypocalcemia have yet to be clarified fully, but
both transcriptional and post-transcriptional mechanisms are
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Figure 2 | The distribution of calcium among various tissue
compartments. A miscible, or rapidly exchangeable, pool of calcium
in bone participates in the regulation of plasma calcium homeostasis
and serves to maintain a constant level of ionized calcium in blood.
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Figure 3 | Plasma PTH levels (triangles, dashed line, left y-axis)
and blood-ionized calcium concentrations (right y-axis) at 1-min
intervals in a volunteer with normal renal and parathyroid gland
function. Note that plasma PTH levels fluctuate over time, consistent
with pulsatile PTH release that is regulated by the CaSR. In contrast,
blood-ionized calcium levels remain constant (Goodman,
unpublished observations).
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Figure 4 | Plasma PTH levels rise abruptly (a) when blood-ionized
calcium concentrations are lowered (b) during intravenous
infusions of sodium citrate both in normal volunteers and in
patients with bone biopsy-proven hyperparathyroidism due to
CKD. Maximum levels are reached within 10–20 min, but values do
not increase thereafter despite a continued decrease in blood-ionized
calcium (from Ramirez et al.43).
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probably involved. First, a CRE that negatively regulates pre-
pro-PTH gene transcription has been identified approxi-
mately 3.6 kb upstream from the transcriptional start site
(Figure 5).47,48 To the extent that decreases in blood-ionized
calcium concentration lower cytosolic free-calcium levels
and/or diminish calcium-mediated signaling in parathyroid
cells, a reduction in calcium-response element-dependent
inhibition of pre-pro-PTH gene transcription would be
expected to enhance PTH mRNA abundance as reported
previously.14,49 Other mechanisms such as changes in the
frequency and/or the amplitude of oscillations in cytosolic
free-calcium concentrations may also contribute.19 Because
transcriptional mechanisms are involved, the time course of
these adaptive responses in parathyroid tissue is substantially
greater than that described previously for calcium-regulated
PTH secretion. Many hours are required for them to affect
calcium metabolism systemically.
Second, hypocalcemia has been reported to stabilize the
mRNA for PTH and prolong its half-life.50,51 The effect
appears to be mediated by cytosolic proteins that bind to
PTH mRNA and interfere with its degradation by endopep-
tidases within parathyroid cells. Increases in PTH mRNA
stability thus promote message translation at the ribosomal
level, increase the amount of PTH produced by each
parathyroid cell, and provide more of the hormone that
can be stored in secretory granules for subsequent release into
the circulation by calcium-regulated secretory signals. The
interval required to modify PTH mRNA stability and to alter
peptide synthesis at the ribosomal level after a reduction in
serum calcium concentration has not been established, but it
is likely to be several hours at least.
Finally, the level of activation of the CaSR affects multiple
intracellular signal transduction pathways including those
mediated by G-proteins, protein kinase C, mitogen-activated
protein kinases, and discrete elements in the cytoskele-
ton.30,52–54 Because increases in signaling through the CaSR
diminish PTH gene expression as judged by changes in
mRNA levels, it is possible that decreases in the CaSR-
dependent signaling exert reciprocal effects to increase PTH
mRNA levels and thus enhance PTH gene expression. More
information is needed, however, to further define the
signaling pathways and molecular mechanisms that regulate
PTH secretion and synthesis.
Apart from increases in PTH secretion and synthesis,
additional adaptive mechanisms are invoked to maintain
blood-ionized calcium levels if signaling through the CaSR
persists for more than 12–24 h. Both low-ambient calcium
levels and high-ambient PTH levels directly stimulate activity
of the renal 25-hydroxyvitamin D-1-a-hydroxylase and
increase the production of calcitriol, or 1,25-dihydroxyvita-
min D, by the kidney.55 Calcitriol acts as a systemic hormone
to promote intestinal calcium transport and to facilitate
calcium mobilization from bone. It also enhances the
reclamation of calcium from tubular fluid in the distal
nephron.
Calcitriol promotes the trans-epithelial movement of
calcium ions in intestinal and renal epithelia by several
mechanisms. The calbindins are vitamin D-dependent
proteins that buffer the concentration of free-calcium ions
within cells and participate in the translocation of calcium
from the apical to the basolateral cell membrane in calcium-
transporting epithelia.56 Calcitriol also increases the expres-
sion of two proteins that belong to the vanilloid family of
transient receptor potential (TRP) proteins, TRPV-5 and
TRPV-6.57–62 Each is a constitutively activated calcium
channel that mediates calcium uptake across the apical
membrane of renal and intestinal epithelial cells, respectively.
Recent work indicates that calcium entry into the cell
through the apical membrane represents the rate-limiting
step for the trans-epithelial movement of calcium in calcium-
transporting epithelia.63 Vitamin D-regulatory elements have
been identified in the promoter region of the genes for both
TRPV-5 and TRPV-6. The hormonal action of calcitriol to
upregulate the expression of TRPV-5, TRPV-6, and the
calbindins thus provides a molecular mechanism to account
for vitamin D-mediated increases in the amounts of calcium
entering the extracellular fluid from the kidney and intestine,
which serve to raise serum calcium concentrations.
Because several mechanisms contribute to the mainte-
nance of blood-ionized calcium levels systemically, overt
hypocalcemia does not develop unless one or more adaptive
responses prove inadequate. In other words, elevated plasma
PTH levels due to increases in PTH synthesis and secretion,
either alone or together with increases in renal calcitriol
production, are sufficient to prevent overt reductions in
blood-ionized calcium concentration unless other distur-
bances interfere with these compensatory responses. Specific
examples include hypovitaminosis D or overt vitamin D
deficiency, prolonged dietary calcium restriction, genetic
disorders such as vitamin D-dependent rickets owing to
inactivating mutations of the renal 25-hydroxyv itamin D-1-
a-hydroxylase, vitamin D-resistant rickets owing to muta-
tions in the VDR, and CKD.
In CKD, low levels of expression of the classical receptor
for PTH, or PTH1R, in target tissues such as the kidney and
bone may contribute to suboptimal biological responses to
PTH that attenuate the capacity of PTH to maintain serum
calcium concentrations.64 Such changes could account, at
least in part, for the tissue-resistance to PTH described
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Figure 5 | A graphic depiction of the vitamin D response element
(VDRE) and the calcium-response element (CRE) located
upstream from the gene for pre-pro-PTH. Both elements
negatively regulate gene transcription.
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previously among patients with CKD.65 Other factors such as
the accumulation of N-terminal-truncated peptide fragments
of PTH acting through putative C-terminal PTH receptors,
or C-PTH receptors, have also been suggested to adversely
affect plasma calcium homeostasis in CKD.66–69 Additional
work is required, however, to clarify adequately and to
elucidate fully the mechanisms involved.
The presence of the CaSR on the cell membrane of
parathyroid cells not only makes it possible for the
parathyroid glands to detect the need for initiating
compensatory responses to maintain blood-ionized calcium
levels but also to determine the adequacy of these responses.
The parathyroids thus function as the pivotal regulator of
plasma calcium homeostasis by modulating calcium entry
into and egress from the extracellular fluid by way of the
distal nephron, bone, and intestine in a manner that is
integrated closely.
In some circumstances, increases in PTH synthesis and
secretion and the responses they elicit are insufficient to
maintain blood-ionized calcium concentrations and to offset
fully the stimulus that led initially to a rise in calcium-
regulated PTH secretion by the parathyroids. As a result,
parathyroid gland enlargement due to tissue hyperplasia may
develop as a final compensatory response to sustain blood-
ionized calcium levels.6,70 Unlike the rapid, short-term
adaptive mechanisms described previously that affect PTH
secretion and synthesis at the level of individual parathyroid
cells, parathyroid gland hyperplasia occurs more gradually,
usually over many months or several years. Although some
studies in rodents suggest that parathyroid gland enlargement
can occur within few days or several weeks,33 observations
from other experimental animal models indicate that the
process proceeds more slowly.70 The end result is an increase
in parathyroid gland mass. As such, more parathyroid tissue
and many more parathyroid cells are available for PTH
synthesis and secretion. The development of parathyroid
gland hyperplasia thus represents the ultimate long-term
adaptive response to circumstances where calcium entry into
the extracellular fluid remains suboptimal for protracted
periods and it arises largely from ongoing calcium-dependent
signaling via the CaSR.
Apart from its role in regulating calcium metabolism,
PTH also has important effects on phosphorus homeostasis
by modulating phosphorus reabsorption within the proximal
nephron. This is accomplished by PTH-dependent changes in
the localized abundance of the type 2 sodium-dependent
phosphate cotransporter in the luminal brush-border mem-
brane of proximal tubular epithelial cells.71,72 The ability of
PTH to promote renal phosphorus excretion thus serves to
attenuate increases in serum phosphorus levels that would be
expected to occur when PTH secretion is enhanced as an
adaptive response to hypocalcemia, a change that stimulates
renal calcitriol production and thus promotes the intestinal
absorption of both calcium and phosphorus. Similar
considerations apply to PTH-mediated increases in the
mobilization of calcium and phosphorus from bone. Again,
increases in serum phosphorus levels would be expected
under these circumstances unless PTH did not concurrently
enhance renal phosphorus excretion.
PATHOGENESIS OF SHPT IN CKD
Divergent views about the pathogenesis of SHPT in CKD
have emerged recently.2,73,74 Abnormalities in calcium
metabolism are considered by some to be the most
immediate cause of SHPT because of the pivotal role of
specific molecular signaling pathways, such as those mediated
by the CaSR, in regulating parathyroid gland function not
only in persons with normal renal function but also in those
with CKD. This molecular-based view is supported by
observations from human and mouse genetic studies
indicating that calcium-dependent signaling specifically
affects three discrete components of parathyroid function
which include PTH secretion, PTH gene expression, and
parathyroid cell proliferation.2,19,75
In contrast, others consider SHPT to be a consequence of
certain biochemical abnormalities which arise due to the
progressive loss of renal function and that directly affect
parathyroid gland function.7,76–80 In this context, most
discussions about SHPT due to CKD have focused primarily
on disturbances in phosphorus metabolism and functional
vitamin D deficiency, more specifically calcitriol deficiency, as
key pathogenic mechanisms, but the actions of phosphorus
and vitamin D on various components of parathyroid gland
function have been defined less clearly.
Investigations begun originally during the early 1970s and
continued subsequently indicate that phosphorus retention
and hyperphosphatemia can aggravate SHPT in experimental
animal models of CKD and that reductions in phosphorus
intake can attenuate disease progression and/or lower serum
PTH levels.76–78 Dietary phosphorus restriction was shown
subsequently to lower serum PTH levels among patients with
CKD who did not yet require treatment with dialysis.80,81
These clinical and experimental observations thus serve as the
basis for the concept that decreases in renal function lead to
reductions in phosphorus excretion in the urine and to
phosphorus retention systemically, resulting ultimately in
hyperphosphatemia and the development of SHPT.
Transient decreases in blood-ionized calcium concentra-
tion due to episodic increases in serum phosphorus levels
were suggested originally to account for the rise in PTH levels
as renal function declined.76 This sequence of events,
described originally as the ‘trade-off ’ hypothesis, is not
supported, however, by other clinical and experimental
observations82 and the findings are most probably attribu-
table to the experimental protocol utilized in the initial
reports. Indeed, increases in serum phosphorus concentra-
tion are a late rather than an early consequence of progressive
CKD.9,83 Results from both cross-sectional studies and
population-based surveys indicate that serum phosphorus
levels remain within the normal range in most patients until
the glomerular filtration rate has fallen to 10–15% of
normal.7,9,83 By contrast, plasma PTH levels are commonly
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elevated among persons with less advanced renal disease,
including many with stages 3 and 4 and some with stage 2
CKD.7–9
Nevertheless, a considerable amount of work has been
done to define a role for abnormal phosphorus metabolism
as a pathogenic factor for SHPT due to CKD. The current
prevailing view is that phosphorus retention and/or hyper-
phosphatemia aggravate SHPT directly.84 Several mechan-
isms have been proposed, including effects on PTH secretion,
PTH gene expression, and parathyroid gland hyperplasia.85–87
Each will be discussed subsequently, but there is only limited
evidence to suggest that abnormalities in phosphorus
metabolism directly affect these discrete components of
parathyroid gland function.85,86 Rather, indirect effects
mediated by phosphorus-induced alterations in calcium
and/or vitamin D metabolism are more likely to account
for changes in parathyroid gland function in CKD.
In this regard, phosphorus is an important modifier of the
level of activity of the renal 25-hydroxyvitamin D-1-a-
hydroxylase, the enzyme responsible for the synthesis of 1,25-
dihydroxyvitamin D or calcitriol, the most potent metabolite
of vitamin D.88 Calcitriol is produced in cells of the proximal
nephron after the reabsorption of 25-hydroxyvitamin D, the
major circulating form of vitamin D, and its binding protein
from proximal tubular fluid by a megalin-dependent
mechanism.89 Calcitriol is subsequently released into the
circulation where it functions systemically as a calcium-
regulating hormone. Cross-sectional studies showing that
circulating 1,25-dihydroxyvitamin D levels decline as a
function of glomerular filtration rate suggest that CKD
represents a state of progressive functional calcitriol
deficiency as judged by low serum levels of the biologically
most potent metabolite of vitamin D.7,90,91
In humans and in experimental animals with normal
kidney function, phosphorus restriction promotes, whereas
phosphorus surfeit diminishes, activity of the 25-hydroxyvi-
tamin D-1-a-hydroxylase in the kidney.88,92,93 As such,
dietary maneuvers designed to modify phosphorus balance
and/or lower serum phosphorus levels in vivo enhance
enzyme activity and increase endogenous calcitriol produc-
tion. In CKD, the regulation of renal 25-hydroxyvitamin D-1-
a-hydroxylase activity is disrupted and the capacity to
synthesize calcitriol diminishes as renal function declines.
Wide variations in serum calcitriol levels are seen, however, at
any particular level of renal function.7,9,91,94 Thus, some
patients with only modest renal functional impairment have
normal serum calcitriol levels, whereas others have values
that are reduced substantially. Similarly, many individuals
with advanced CKD have subnormal levels of calcitriol in
serum, but some have values that remain within the normal
range.
The explanation for such wide variations in serum
calcitriol levels among patients with CKD is not known,
but differences in vitamin D nutrition may play a role.
Inadequate vitamin D nutrition is common not only in
persons from the general population but also among patients
with CKD94–96 and it may compromise renal calcitriol
production by limiting the amount of substrate, that is 25-
hydroxyvitamin D, available for conversion by the renal 25-
hydroxyvitamin D-1-a-hydroxylase. Kidney diseases that
affect the renal tubules and interstitium predominantly may
have disproportionate adverse effects on renal calcitriol
production.90 Although the regulation of renal calcitriol
synthesis is impaired substantially in advanced CKD, renal
calcitriol production is maintained in many patients with
mild to moderate CKD. Serum calcitriol levels thus increase
appropriately and plasma PTH levels decline when dietary
phosphorus intake is reduced in patients with stages 2 and 3
CKD.80
Such findings underscore the physiological impact of
alterations in phosphorus metabolism on the circulating
levels of calcitriol in blood in early stages of CKD and their
important indirect effect to lower plasma PTH levels by
vitamin D-dependent mechanisms. Definitive evidence has
yet to be presented demonstrating that dietary phosphorus
restriction reduces plasma PTH levels directly either in
humans or experimental animals with CKD without
associated changes in the serum levels of calcitriol or
calcium, two key modulators of parathyroid gland function.
Indeed, dietary phosphorus restriction and the administra-
tion of phosphate-binding agents that do not contain
calcium enhance net calcium absorption from the gastro-
intestinal tract by increasing the amount of free calcium ions
in the intestinal lumen that are not associated with, or
complexed to, inorganic phosphorus. Recent data also
implicate both direct and indirect actions of fibroblast
growth factor 23 (FGF-23), which is regulated by phos-
phorus, as a modifier parathyroid gland function (vide infra).
Inadequate renal calcitriol production also provides a
physiological explanation for impairments in intestinal
calcium absorption and for the hypocalciuria and modest
hypocalcemia that characterize untreated patients with
moderate renal insufficiency.97,98 Indeed, hypocalciuria is a
hallmark of mild to moderate renal failure. Because
inadequate calcium absorption from the intestine prompts
adaptive responses by the parathyroid glands to maintain
blood-ionized calcium concentrations as described pre-
viously, SHPT represents a predictable, physiological conse-
quence of progressive CKD.
It has been suggested, however, that elevated serum
phosphorus levels in CKD enhance PTH secretion directly.85
As noted previously, short-term variations in extracellular
calcium concentration have immediate effects on PTH
secretion and these responses have been characterized
extensively both in vivo and in vitro. In contrast, short-term
variations in serum phosphorus levels in vivo do not affect
PTH secretion as judged by changes in plasma PTH levels
over the course of minutes to hours.99 High concentrations of
phosphorus in culture media also do not promote PTH
release from dispersed parathyroid cells or from parathyroid
tissues during short-term incubations in vitro.85 Such
changes occur only during longer incubations lasting 4–6 h,
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a response that can be blunted by the addition of
cyclohexamide, an inhibitor of protein synthesis, to the
culture medium.85 The results are thus most consistent with
an effect of phosphorus on pre-pro-PTH gene transcription
or on post-transcriptional events rather than on PTH
secretion per se.
An additional methodological challenge for studies of
PTH secretion in vitro whether done using dispersed
parathyroid cells or sections of parathyroid tissue is the fact
that the addition of excess amounts of phosphorus to serum-
free media almost invariably lowers the concentration of free-
calcium ions. Such changes are due to the relatively low
solubility of calcium and phosphorus together in aqueous
solutions at physiological pH, particularly in the absence of
proteins such as albumin, which buffer changes in ionized
calcium, and fetuin A, which acts as an inhibitor of calcium
precipitation.100 Other soluble inhibitors of calcification such
as magnesium and citrate are also present normally in
plasma. Among studies reported thus far, adequate doc-
umentation has not been provided to confirm that high
concentrations of phosphorus in serum-free culture media
can be achieved experimentally without lowering the
concentration of ionized calcium, a potent and immediate
stimulus for PTH secretion. The contention that high
phosphorus concentrations modify PTH secretion directly
in vitro thus remains unproven.
As noted previously, abnormalities in phosphorus meta-
bolism, specifically hyperphosphatemia and phosphorus
retention, have been suggested to enhance PTH gene
expression by post-transcriptional mechanisms.51,86,101 The
stability of the mRNA for PTH was reported to diminish, as
judged by an in vitro degradation assay, in rats maintained on
a low-phosphorus diet and to increase in rats fed a calcium-
deficient diet.102 Such changes would thus modify mRNA
translation at the ribosomal level and alter PTH synthesis.
Increases in PTH mRNA stability have yet to be described,
however, either in experimental animals with elevated serum
phosphorus levels or in those ingesting diets containing
excess amounts of phosphorus, perturbations more relevant
to clarifying a role for phosphorus in the pathogenesis of
SHPT. Although PTH mRNA levels increased modestly in
parathyroid tissue obtained from phosphorus-supplemented
rats, the serum levels of 1,25-dihydroxyvitamin D were
twofold lower in this experimental group than in control rats
ingesting a diet containing normal amounts of phos-
phorus.102 Differences in gene expression mediated through
vitamin D-dependent pathways may thus account for the
experimental results.
The role of phosphorus retention as a modifier of
parathyroid gland hyperplasia has been defined more clearly.
Overall, phosphorus retention and hyperphosphatemia
appear to aggravate the process of parathyroid gland
hyperplasia.87,103 The expression of transforming growth
factor-a and its mRNA in parathyroid tissue is enhanced in
subtotally nephrectomized rats maintained on a diet contain-
ing high levels of phosphorus, whereas dietary phosphorus
restriction increases expression of p21, a factor involved in
cell-cycle regulation, at both the protein and mRNA level.87
The effect of phosphorus restriction on p21 expression in
parathyroid tissue was reported to occur without associated
changes in the serum levels of 1,25-dihydroxyvitamin D,
which upregulates p21 expression and contributes to the
antiproliferative actions of 1,25-dihydroxyvitamin D in other
types of cells.104,105 Such findings thus suggest that
phosphorus restriction enhances p21 expression directly with
favorable effects to retard parathyroid cell proliferation and
to diminish parathyroid hyperplasia in an experimental
model of CKD. Moreover, increases in transforming growth
factor-a expression in the parathyroid glands of subtotally
nephrectomized animals ingesting excess amounts of phos-
phorus may provide an additional autocrine signal that
aggravates the hyperplastic process.106,107
It should be acknowledged, however, that all such in vitro
studies have been done in parathyroid tissue obtained from
experimental animals exposed in vivo to diets containing
either very large or very small amounts of phosphorus. These
experimental manipulations can influence vitamin D meta-
bolism systemically with subsequent effects on intestinal
calcium absorption and homeostasis that indirectly modify
parathyroid gland function as discussed previously. In
addition, the recently identified phosphorus-regulating
hormone FGF-23 acts directly on parathyroid tissue, provid-
ing another pathway by which phosphorus and vitamin D
may affect the process of parathyroid gland hyperplasia.108
DISEASE SEVERITY AND DISEASE PROGRESSION
The importance of parathyroid gland hyperplasia as a
determinant of the severity of SHPT has not been appreciated
fully. This may be due, in part, to the lack of reliable methods
for imaging the parathyroid glands to provide useful
information, either for clinical or research purposes, about
the extent of parathyroid gland enlargement. It is often
possible to identify one or more markedly enlarged
parathyroid glands using high-resolution ultrasound in
patients with SHPT, but the technique is usually not
sufficiently sensitive to detect smaller glands or to consis-
tently localize all four parathyroid glands in most patients.
Other methods such as computed tomography, magnetic
resonance imaging, and nuclear medicine techniques have
similar limitations. As such, accurate and reproducible in vivo
measurements of parathyroid gland mass are quite difficult to
obtain.
Several assessments of parathyroid gland function in
patients with either primary hyperparathyroidism or SHPT
provide insight, however, into the role of parathyroid gland
size as a determinant of disease severity.42–44,109–113 Plasma
PTH levels decrease invariably as blood-ionized calcium
concentrations rise during intravenous infusions of calcium
in volunteers with normal renal and parathyroid gland
function.43 Values fall by approximately 90%, or to levels
that are 10–12% of preinfusion values, when blood-ionized
calcium concentrations increase by 0.10–0.15 mmol/l (Figure 6).
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Plasma PTH levels do not decline further, however, as blood-
ionized calcium concentrations continue to rise. Accordingly,
there is a non-suppressible, or constitutive, component of
PTH release from parathyroid tissue that is not regulated by
calcium (Figure 6). This has also been documented
repeatedly in studies of dispersed parathyroid cells in
vitro.13,114,115
The non-suppressible component of PTH secretion is
greater than normal both in patients with primary hyperpar-
athyroidism and in those with SHPT, due primarily to
increases in parathyroid gland mass (Figure 6).42,113 This was
reported originally, and it is best documented, in patients
with surgically-proven primary hyperparathyroidism where
the suppressive effect of intravenous calcium infusions on
plasma PTH levels was shown to diminish as a function of
the size of parathyroid adenomas removed surgically.44 Thus,
smaller percentage reductions in plasma PTH levels were
observed in patients with relatively large parathyroid
adenomas, whereas larger percentage decreases in plasma
PTH from baseline values were seen in patients with small
adenomas. In other words, the non-suppressible component
of PTH secretion became greater as the mass of parathyroid
tissue increased.
Qualitatively similar results were reported among patients
with SHPT due to CKD who required ongoing treatment
with dialysis.113 For these studies, computed tomography and
magnetic resonance imaging were done to obtain estimates of
parathyroid gland size. Although limited by the technical
shortcomings of these methods, as discussed previously, the
results are nonetheless consistent with those described in
patients with primary hyperparathyroidism. Increases in
parathyroid gland mass were associated with smaller
percentage reductions in plasma PTH levels when blood-
ionized calcium concentrations were raised under controlled
experimental conditions.113
Differences in the non-suppressible component of PTH
release were described subsequently between dialysis patients
with established SHPT, as documented by elevated plasma
PTH levels and by bone biopsy, and those with advanced
SHPT who were evaluated shortly before undergoing surgical
parathyroidectomy, a condition often described as tertiary
hyperparathyroidism (Figure 6).42 The non-suppressible
component of PTH secretion was substantially greater in
patients with advanced SHPT than in those with mild to
moderate disease, but values were not as markedly elevated as
in subjects with primary hyperparathyroidism who were
evaluated by the same experimental method.42 Estimates of
the set point for calcium-regulated PTH were also greater
than normal in those with either primary hyperparathyroid-
ism or advanced SHPT. The results of these in vivo studies are
thus consistent with data reported originally from in vitro
assessments of PTH secretion from dispersed parathyroid
cells obtained from patients undergoing surgery for the
treatment of either primary hyperparathyroidism or ad-
vanced SHPT due to CKD.13,114,115 They also demonstrate
that an increase in the set point for calcium-regulated PTH
release is a late rather than an early consequence of
hyperparathyroidism due primarily to parathyroid gland
enlargement, data consistent with observations in mice
homozygous for inactivating mutations of the gene for cyclin
D (cyclin D/) where a set point abnormality develops only
after parathyroid gland mass has increased substantially due
to parathyroid hyperplasia.116,117
Such findings indicate that increases in parathyroid gland
mass, due either to progressive tissue hyperplasia or to the
ongoing enlargement of parathyroid adenomas, increase the
non-suppressible, calcium-independent component of PTH
release from the parathyroid glands. The results are also
consistent with previous experimental work in the rat
demonstrating that overt hyperparathyroidism and hypercal-
cemia can be induced when excess amounts of normal
parathyroid tissue are implanted subcutaneously.118 On-
going, calcium-independent PTH release from the parathy-
roid glands can thus ultimately become sufficient to produce
uncontrolled hyperparathyroidism when the mass of para-
thyroid tissue exceeds a certain critical mass.
The factors that modulate the growth and proliferation of
parathyroid cells are not understood fully. Disturbances in
vitamin D metabolism arising from CKD have been
considered traditionally not only to play a pivotal role in
the development of SHPT but also to contribute materially to
the progression of parathyroid hyperplasia.79,119 Vitamin D
sterols, particularly calcitriol, have antiproliferative effects in
a variety of cell types and they generally promote cell
differentiation.120–123 In addition, expression of the VDR is
reduced in hyperplastic parathyroid tissues obtained
from humans and experimental animals with CKD.124–127 It
has been suggested, therefore, that decreases in VDR
expression render target tissues such as the parathyroids less
responsive to the biological actions of vitamin D, but direct
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Figure 6 | The percentage changes in plasma PTH levels during
intravenous infusions of calcium gluconate in volunteers
with normal renal and parathyroid gland function, in patients
with bone biopsy-proven hyperparathyroidism due to CKD,
in patients with severe SHPT who were few days before
undergoing surgical parathyroidectomy, and in patients with
primary hyperparathyroidism due to parathyroid adenoma.
The non-suppressible component of PTH release differs
substantially from normal in each clinical disorder
(from Goodman et al.42).
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experimental evidence to support this contention has not
been presented.
When assessed by immunohistochemistry, the level of
VDR expression in parathyroid glands removed from patients
with SHPT is lower in tissues with a nodular pattern of
hyperplasia than in tissues with diffuse chief cell hyperpla-
sia.125 Such findings are of interest because nodular
parathyroid gland hyperplasia is generally associated with
more extensive parathyroid gland enlargement.128 Decreases
in the bioavailability of calcitriol systemically and/or changes
in VDR expression in hyperplastic parathyroid tissue may
thus influence the extent and severity of parathyroid gland
enlargement in CKD.
Unfortunately, it is difficult, if not impossible, to assess the
actions of vitamin D on parathyroid cell proliferation
directly. This is due largely to the unavailability of a stable
line of parathyroid cells for ongoing studies in vitro. It thus
remains uncertain whether the antiproliferative effects of
vitamin D as described in vitro in other cells also apply to
parathyroid cells. Experiments in genetically modified mice
indicate, however, that vitamin D-dependent pathways play a
secondary rather than a primary role in the regulation of
parathyroid gland hyperplasia.
Mice that are homozygous (VDR/) for inactivating
mutations of the VDR represent one genetic model of
vitamin D deficiency.129 The tissues of VDR/ animals are
unable to respond to vitamin D because the molecular
mechanism for mediating the classical actions of vitamin D
has been disrupted. Consequently, VDR/ mice develop all
of the cardinal manifestations of vitamin D deficiency,
including hypocalcemia, elevated plasma PTH levels, marked
parathyroid gland hyperplasia, hypophosphatemia, osteoma-
lacia in bone, and rachitic changes in epiphyseal growth-plate
cartilage.129 Serum calcium levels can be maintained within
the normal range, however, by feeding VDR/ animals a
diet containing 2.0% calcium supplemented with lactose to
enhance passive, vitamin D-independent intestinal calcium
transport.130 As a result, plasma PTH levels and serum
calcium and phosphorus concentrations remain normal and
parathyroid gland hyperplasia does not occur.130 Adequate
signaling through the CaSR is thus sufficient to prevent
SHPT and parathyroid gland hyperplasia even in tissues that
are incapable of responding to vitamin D.
Despite these findings, recent studies using other murine
genetic models suggest additional potential mechanisms that
could influence the process of parathyroid hyperplasia
tissue.131,132 Mice that are homozygous (1aOHase/) for
inactivating mutations of the renal 25-hydroxyvitamin D-1-
a-hydroxylase also develop overt manifestations of vitamin D
deficiency due to the inability of the kidney to synthesize
calcitriol.131 The serum levels of calcitriol in these animals are
undetectable. As expected, calcitriol administration nor-
malizes serum calcium concentrations and prevents parathyr-
oid gland enlargement in 1aOHase/ mice, whereas restoring
serum calcium levels to normal by dietary calcium sup-
plementation was reported to attenuate but not fully
prevent parathyroid gland enlargement.132 The results
thus differ strikingly from those described previously in
VDR/ mice.
Although CaSR expression in parathyroid tissue was not
assessed in these studies,132 vitamin D-mediated differences
in CaSR expression via classical genomic mechanisms are
probably not responsible for the disparate effects of dietary
calcium supplementation on parathyroid hyperplasia in
1aOHase/ and VDR/ mice. The pathway is inactive in
both experimental models. Marked disparities in plasma
calcitriol levels have thus been invoked to account for these
findings. Plasma calcitriol levels are very high in VDR/
mice but they are undetectable, as noted previously, in
1aOHase/ mice. As such, biological actions of vitamin D
mediated through a non-genomic pathway, perhaps via a
membrane-associated receptor as described by others, might
act to prevent parathyroid hyperplasia in calcium-supple-
mented VDR/ mice, whereas the absence of calcitriol in
1aOHase/ mice would preclude such an effect in
parathyroid tissue.132–135
It is unlikely, however, that non-genomic effects of
vitamin D due to marked differences in serum calcitriol
levels account for the reported differences in parathyroid
gland size between VDR/ and 1aOHase/ mice after
serum calcium concentrations have been restored to normal
by dietary calcium supplementation. Treatment of VDR/
mice with exogenous doses of calcitriol achieved serum
calcitriol levels that were two- to threefold higher than values
determined in untreated VDR/ mice, but this biochemical
change was insufficient to prevent parathyroid gland
hyperplasia.132 Similar results were obtained after treatment
with calcitriol in double-mutant mice with inactivating
mutations of both the VDR and the renal 25-hydroxyvitamin
D-1-a-hydroxylase (VDR//1aOHase/).132 High serum
calcitriol levels would be expected to retard parathyroid
hyperplasia in both experimental models if non-genomic
mechanisms were involved. Additional work is required to
resolve this issue, but the data available currently are
insufficient to establish a definitive role for a non-genomic
mechanism of action for vitamin D in the control of
parathyroid gland hyperplasia.
Apart from effects attributable to vitamin D, parathyroid
gland hyperplasia is a prominent feature in mice with
inactivating mutations of the CaSR.136 Mice that are
heterozygous (CaSRþ /) for inactivating mutations of the
CaSR have moderate parathyroid gland enlargement, whereas
animals homozygous (CaSR/) for inactivating mutations
of the CaSR have extensive tissue hyperplasia.136,137 Such
changes occur despite markedly elevated serum levels of 1,25-
dihydroxyvitamin D in CaSR/mice, results that again
highlight the importance of calcium-dependent signaling as
opposed to vitamin D-mediated pathways as a key determi-
nant of parathyroid gland hyperplasia. Familial hypocalciuric
hypercalcemia and neonatal hypercalcemia are the cor-
responding clinical conditions in humans represented by
these two murine genetic models.138,139 Parathyroid gland
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enlargement occurs in both, but it is much more extensive
among patients with neonatal hypercalcemia. Mice
with inactivating mutations of the both the CaSR and the
gene for PTH (CaSR//PTH/) also exhibit marked
parathyroid gland hyperplasia emphasizing further the
crucial role of inadequate calcium-sensing via the CaSR
rather than a demand for excess PTH production as the
proximate cause of parathyroid gland enlargement in this
genetic model.140 Overall, the results of these investigations
offer additional evidence that defects in calcium sensing at
the molecular level in parathyroid cells lead to parathyroid
gland hyperplasia.
Signaling via the CaSR has been shown to influence cell
proliferation and cellular differentiation in a variety of tissues
and may contribute to the previously described effects of
vitamin D on cell proliferation and differentiation.122,141,142
Two vitamin D-response elements have been identified
within the promoter region of the gene that encodes the
CaSR, and calcitriol has been reported to enhance CaSR
mRNA expression.143 Although enhanced calcium-dependent
signaling via the CaSR may thus participate in the
antiproliferative actions of vitamin D in some cells, it is
not yet known whether these interactions influence cell-cycle
regulation in parathyroid tissue or the process of parathyroid
gland hyperplasia in SHPT.
Other molecular pathways are also likely to be involved in
modulating parathyroid gland function and PTH secretion in
CKD. As mentioned previously, parathyroid tissue has been
noted to be a target for FGF-23 (unpublished observations), a
phosphaturic factor produced predominately by osteocytes in
bone.144,145 The production of FGF-23 is regulated by
phosphorus and by vitamin D as well as by several factors
that control matrix mineralization, including matrix extra-
cellular phosphoglycoprotein and dentin matrix protein 1.146
The serum levels of FGF-23 are elevated markedly in patients
with CKD and enhanced FGF-23 production may serve,
along with PTH, to attenuate or prevent hyperphosphatemia
as kidney function declines.147,148 Because phosphorus,
vitamin D, and CKD each increase FGF-23 expression, this
key regulator of phosphorus metabolism may affect para-
thyroid gland function among patients with impaired renal
function.
The presence of hyperparathyroidism in murine genetic
models characterized by overproduction of FGF-23 further
suggests that this hormone contributes either directly or
indirectly to the development of hyperparathyroidism. Renal
1a´-hydroxylase activity is impaired by FGF-23 leading to
decreases in calcitriol synthesis and reductions
in serum 1,25(OH)2 D levels.
149 Notably, the product of
the klotho gene has been shown to interact with several
FGF receptors and to increase their affinity for FGF-23.150,151
Interactions among FGF-23, klotho, and renal calcitriol
production may thus secondarily influence parathyroid
gland function in CKD. Additional work is needed to
clarify the role of FGF-23 in the pathogenesis of SHPT due
to CKD.
SUMMARY
The identification of the CaSR and the clarification of its role
as the major regulator of parathyroid gland function have
important implications for understanding the pathogenesis,
evolution, and treatment of SHPT in CKD. Signaling through
the CaSR has direct effects on three discrete components of
parathyroid gland function, which include PTH secretion,
PTH synthesis, and parathyroid gland hyperplasia. Distur-
bances in calcium and vitamin D metabolism that arise due
to CKD diminish the level of activation of the CaSR, leading
to increases in PTH secretion, PTH synthesis, and parathy-
roid gland hyperplasia. Each represents a physiological
adaptive response by the parathyroid glands to maintain
plasma calcium homeostasis. Studies of genetically modified
mice indicate that signal transduction via the CaSR is a key
determinant of parathyroid cell proliferation and parathyroid
gland hyperplasia. Because enlargement of the parathyroid
glands has important implications for disease progression
and disease severity, it is possible that clinical management
strategies which maintain adequate calcium-dependent
signaling through the CaSR will ultimately prove useful in
diminishing parathyroid gland hyperplasia and in modifying
disease progression.
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